RSV with a weakened immune system

For people with a healthy immune system, RSV is an unpleasant cold that resolves on its own. For immunocompromised individuals — transplant recipients, people undergoing cancer treatment, those on immunosuppressive medications for autoimmune conditions — RSV can become a life-threatening lower respiratory infection. The virus that healthy adults barely notice can progress to severe pneumonia in someone whose immune system can't contain it.

This guide covers how RSV behaves differently in immunocompromised patients, what escalation looks like, and what protection options are currently available.

Who is considered immunocompromised for RSV purposes?

The degree of immune compromise matters — a person on low-dose methotrexate for rheumatoid arthritis faces a different RSV risk than someone who received a bone marrow transplant six months ago. Higher-risk groups include:

• Hematopoietic stem cell transplant (HSCT) recipients — especially in the first year post-transplant, when immune reconstitution is incomplete
• Solid organ transplant recipients on long-term immunosuppression
• People receiving active chemotherapy for hematologic malignancies (leukemia, lymphoma, multiple myeloma)
• People on high-dose corticosteroids (prednisone ≥20 mg/day for extended periods)
• People with primary immunodeficiency disorders
• People on biologic therapies that significantly suppress immune function (anti-CD20 agents like rituximab, for example)

How RSV behaves differently in immunocompromised patients

The normal pattern of RSV illness — upper respiratory infection for a few days, then resolution — may not apply in immunocompromised patients. Key differences:

• Longer upper respiratory phase. The virus may persist in the upper airways for weeks rather than days before (or instead of) clearing.
• Higher rate of progression to lower respiratory disease. In healthy adults, RSV progresses to pneumonia or bronchitis in a small fraction of cases. In stem cell transplant patients, progression rates to lower respiratory tract disease can be 30–40% or higher.
• More severe lower respiratory disease. RSV pneumonia in immunocompromised patients can progress to respiratory failure requiring mechanical ventilation, with mortality rates significantly higher than in the general population.
• Prolonged viral shedding. Immunocompromised patients shed RSV for much longer — sometimes weeks — after infection begins, which has implications for infection control in household and healthcare settings.
• Blunted or absent fever. Fever is a less reliable symptom in immunocompromised patients because the immune response that produces fever may be suppressed. Don't rely on absence of fever as reassurance.

RSV vaccines in immunocompromised adults

The adult RSV vaccines (Abrysvo, mRESVIA) are not contraindicated in immunocompromised patients, but their effectiveness may be reduced depending on the degree of immune suppression. Several considerations:

• Timing relative to treatment. Vaccines generally work better when administered outside of active immunosuppression. For transplant patients, this often means vaccinating before transplant or during a period of lower immunosuppression. Your transplant team will have specific guidance.
• Reduced immune response. Immunocompromised patients may not mount the same antibody response as healthy adults, meaning the protection from vaccination may be partial. It's still generally recommended, as some protection is better than none.
• Coordination with your specialist. The decision about RSV vaccination timing should be made in collaboration with your oncologist, transplant team, or rheumatologist — not independently.

What about antiviral treatment?

There is currently no FDA-approved antiviral specifically for RSV in adults. Aerosolized ribavirin has been used off-label in severe RSV cases in immunocompromised patients in hospital settings, but evidence for its effectiveness is limited and it is not a standard outpatient treatment. Research on RSV antivirals for adults is ongoing.

Early recognition and supportive care — supplemental oxygen, airway management, treatment of secondary bacterial infections — remain the mainstay of management for severe RSV in immunocompromised patients.

Reducing RSV exposure

For immunocompromised individuals, prevention through exposure reduction is especially important given that vaccine response may be incomplete and no effective antiviral exists:

• Wear a high-quality mask (N95 or equivalent) in crowded indoor settings during RSV season
• Ask visitors with cold symptoms to reschedule or meet outdoors
• Hand hygiene before and after contact with others
• Ask household members to report cold symptoms early so you can take precautions
• Avoid healthcare waiting rooms with respiratory illness patients if possible — schedule appointments at off-peak hours

Not medical advice. RSV management in immunocompromised patients is highly specialized. All decisions about vaccination, treatment, and exposure management should be made in collaboration with your medical team. In an emergency, call 911.